Regulatory history Despite recent negative press history, Insys Therapeutics remains a commercial-stage company with marketed products Subsys and Dronabinol SG Capsule, indicating potential for ongoing revenue streams that can be leveraged through renewed compliance-focused partnerships and distribution agreements.

Product portfolio Focused on pain management and CINV with sublingual fentanyl spray and dronabinol capsule, suggesting sales opportunities with oncology clinics, hospices, and specialty pharmacies seeking central nervous system and breakthrough pain solutions.

Technology stack Proven digital and cloud capabilities (AWS, Drupal, Google services) can support modernized digital marketing, e-commerce, and e-detailing efforts to reach prescribers and healthcare facilities, enabling efficient sales outreach.

Revenue potential Reported revenue range indicates moderate scale; opportunities exist to expand payer partnerships, optimize formulary access, and explore co-pay assistance programs to drive adoption of existing products.

Market positioning Presence in specialty pharmaceuticals with a focus on supportive care positions the company to pursue partnerships in oncology care pathways, hospital-based formularies, and distribution channels seeking niche CNS and pain management therapies.